Abstract
Introduction
The present literature lacks an endotype- or anatomical site-targeted synthesis of the studies advocating for periostin upregulation in nasal polyps (NPs).
Objectives
Differences in periostin levels between NP samples from different CRSwNP endotypes, NP and normal controls, NP and nonpolypoidal mucosal samples (MSs) within chronic rhinosinusitis with nasal polyposis (CRSwNP) patients, and MS from CRSwNP patients and controls were considered as primary outcomes.
Data synthesis
Eosinophilic NP (eNP) samples exhibited significantly higher periostin levels than non-eNP, while non-eNP samples were found to be comparable to controls. Comparisons between NP and MS of patients with CRSwNP attributed significantly higher periostin mRNA and protein levels in the former, while the MS of patients with CRSwNP were comparable to controls and CRSsNP. A strong correlation between mRNA and protein periostin measurements was verified.
Conclusion
Periostin is highly associated with eosinophilic CRSwNP and significantly upregulated in mature eNP rather than nonpolypoidal mucosa.
Keywords: periostin, chronic rhinosinusitis with nasal polyposis, biomarker, eosinophilic
Introduction
Periostin is an extracellular matrix protein, which promotes cell adhesion, autocrine activation and collagen fibrinogenesis in response to injury and inflammation. 1 2 3 Over the past decade, the upregulation of periostin in nasal polyp (NP) tissue samples of patients with chronic rhinosinusitis (CRS) with nasal polyposis (CRSwNP) compared with controls has triggered broad research on the possible pathogenetic role of periostin and its potential use as a biomarker/therapeutical target in the treatment of CRSwNP.
The present systematic review targets a better insight into the role of periostin in the pathophysiology of CRSwNP, by determining the details of periostin upregulation regarding different CRSwNP endotypes, different sites of the nasal mucosa, and CRS patients without CRSsNP. The second question will be summarized through the differences between mature NP tissue samples and nonpolypoidal mucosal samples (MSs) collected from different adjacent anatomical sites within the same CRSwNP patients, in comparison with normal controls. The clinical usefulness of periostin as a potential biomarker, as well as variances in the methodology used by different research groups, were also evaluated and discussed.
Methods
This review adhered to the guidelines of the Preferred Reporting Items of Systematic Reviews and Meta-Analysis (PRISMA) statement. 4 5 Prospective and retrospective studies referring to periostin levels in NP, MS, nasal secretions or serum were all eligible for inclusion.
A review of the present literature was conducted in the PubMed CENTRAL, and Openmd.com databases. The pubmed search was conducted for human studies only and time-limited for the period January 2008 to June 2025. With these limits applied, the search terms periostin and sinusitis attributed 75 results and the terms periostin and nasal polyp attributed 67 results. In Openmd.com the same search terms produced 39 and 48 results respectively. No relevant/similar reviews appeared from the search in CENTRAL database. Articles written in Chinese were excluded.
The procedure is presented as a flowchart in Fig. 1 . The study inclusion criteria have been described in detail in a previous publication. 6 7 8
Fig. 1.

Study selection flowchart.
Two investigators (OA and MR) independently decided on the study eligibility and extracted data from full text manuscripts.
We considered as primary outcomes the differences in periostin mRNA and protein levels between CRSwNP patients and normal controls. Both NP and MS (such as uncinate process [UP], inferior/middle turbinate, or other non-polypoidal mucosal tissue samples) taken from CRSwNP patients were compared with controls. We also considered as primary outcomes the differences in periostin levels between NP and MS within the same CRSwNP patients and among different CRSwNP endotypes. Secondary outcomes included the accordance between mRNA and protein measurements, the conformity between different laboratory methods of measuring periostin and the differences between CRSwNP and CRSsNP patients.
The Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool was used to evaluate the included studies. 5 The tool consists of 4 domains; 1) patient selection, 2) index test (in this study periostin measurements), 3) reference standard (in this study CRSwNP diagnosis, including any endotype assessment), 4) flow and timing between the diagnosis of CRSwNP and measurements of periostin levels.
Βased on the bias factors determined in a previous review, 8 a high risk for selection bias was attributed if ≥3 of the following bias factors were unknown or significantly different among study groups; asthma, non-steroidal anti-inflammatory drug exacerbated respiratory disease (NERD), atopy, disease severity (assessed with polyp size, clinical or radiological severity), and local or systemic steroid treatment ( Table 1 ).
Table 1. Patient selection bias.
| N | Study | Asthma | NERD | Atopy | Severity | Glyco-corticosteroids | Other interventions | Eosinophilic endotype |
|---|---|---|---|---|---|---|---|---|
| Studies on tissue samples | ||||||||
| 1 | Stankovic et al., 2008 20 | NS (CRSwNP vs. CLS) | Excl | ? | Bilateral NP, frontal and/or sphenoid incl | Oral excl | ? | No |
| 2 | Platt et al., 2011 30 | CRSwNP > CLS | Excl | ? | Pansinusitis & NP grade 3 | Oral excl | ? | No |
| 3 | Ishida et al., 2012 9 | CRSwNP > CLS | Subgroup | Study subgroup | CT ± SD 3.5 ± 0.6 |
Oral excl | No immune-modulating drugs | No |
| 4 | Kim et al., 2015 10 | NS (E vs. NE) | ? | IgE Ab against 6 mixtures of common aeroallergens> 3.51 kU/L; E > NE | L-M [15(10-20) vs. 16(10-22)], E/M ratio, olfactory cleft opacification | Syst & IN excl | No antibiotics, antihistamines or Immune-modulating drugs |
Yes |
| 5 | Seshardi et al., 2015 33 | CRSwNP > CLS | ? | ?; CRSwNP > CLS | ? | ? | ? | No |
| 6 | Shiono et al., 2015 21 | Diffuse > superficial periostin | None | NS | ? | ? | ? | Yes |
| 7 | Wang et al., 2015 22 | NS | NS | Skin prick test +; NS | mean (range) L-M: 14 (2-24) NP grade: 1.5 (0.5-3) |
Syst & IN excl | No antibiotics | Yes |
| 8 | Gevaert et al., 2017 28 | NS (CRSwNP vs. CLS) | ? | NS (CRSwNP vs. CLS) | ? | Syst & IN excl | ? | Yes |
| 9 | Kim et al., 2017 23 | NS | Excl | IgEAb for 6 mixtures of aeroallergens and tissue total IgE; NS | ? | Syst & IN excl | No antibiotics, antihistamines or immune-modulating drugs | Yes |
| 10 | Xu et al., 2017 11 | NS | ? | ? | ? | Syst & IN excl | ? | Yes |
| 11 | Wei et al., 2018 27 | CRSwNP > CLS Among CRSwNP E asthma = 9 and NE asthma = 5 |
NS | Skin prick tests CRSwNP > CLS |
(mean ± SD) L-M: 15.8 ± 10 NP grade: 2 ± 0.8 |
? | ? | Yes |
| 12 | Wu et al., 2018 29 | E-CRSwNP > CLS | NS | Skin prick tests NS |
(mean ± SD) L-M: 15.7 ± 4.3 L-K: 6.7 ± 2.6 |
Syst & IN excl | No antibiotics | Yes |
| 13 | Wu et al., 2018 12 | CRSwNP > CLS | NS | NS | (mean ± SD) L-M: 15.7 ± 4.3 L-K: 6.7 ± 2.6 |
Syst & IN excl | No antibiotics | Yes |
| 14 | Nakayama et al., 2019 13 | E > NE | NS | ? | L-M, NP grade mean ± SD by groups | Oral excl | No antibiotics | Yes |
| 16 | Du et al., 2021 15 | NS | NS | CRSwNP > CLS | mean (range) L-M: 14 (2-24) |
Syst & IN excl | No antibiotics | Yes |
| 17 | Yilmaz et al., 2022 19 | CRSwNP > CLS | CRSwNP > CLS | CRSwNP > CLS Diagnosis of allergy only with history |
(mean ± SD) L-M: 19.9 ± 4 |
Syst & IN excl | ? | Yes |
| 18 | Zhang et al., 2022 16 | NS | ? | NS | (mean ± SD) Normosmic: L-M: 9.5 ± 6.5 L-K: 4.4 ± 3.7 Hyposmic: L-M: 15.6 ± 7 L-K: 7.2 ± 3.3 |
Oral excl | ? | Yes |
| 19 | Danielides et al., 2025 17 | Investigated as bias factor | ? | ? | ? | Syst & IN excl | Smoking tested as bias factor | No |
| 20 | Maharani et al., 2025 18 | NS, 1/30pts | Excl | excl | (mean ± SD) L-K: 1.4 ± 0.8 L-M: 13.2 ± 6.3 |
Syst & IN excl | No antibiotics | Yes |
| 21 | Suzaki et al., 2025 25 | CRSwNP > CLS E > NE |
CRSwNP > CLS E > NE |
? | ? | Syst excl | Yes | |
| Studies on serum and/or nasal secretions | ||||||||
| 22 | Asano et al., 2017 31 | All asthmatic | NS | IgEAb for 8 common aeroallergens; NS | L-M for each pt in dot plots | Oral excl | No immune-modulating drugs | Yes |
| 23 | Maxfield et al., 2017 32 | CRSwNP > CLS | CRSwNP > CLS | ? | ? | Multivariate regression analysis; NS | ? | No |
| 24 | Xu et al., 2017 26 | NS | ? | ? | ? | Syst & IN excl | excl | Yes |
| 25 | Wu et al., 2021 14 | Uncontrolled > controlled CRSwNP | Excl | Uncontrolled > controlled CRSwNP | ? | Syst & IN excl | No antibiotics or immune-modulating drugs | Yes |
Abbreviations: ?, not reported; Ab, antibodies; CLS, controls; CT, computed tomography; E/M ratio, ethmoid/maxillary L-M score ratio; excl: excluded from study population; IN, intranasal; L-K, Lund Kennedy score; L-M, Lund McKay score; NS, nonsignificant between study groups; NSAID, nonsteroidal anti-inflammatory drugs; pts, patients; syst, systemic. Notes: > indicated significant difference between study groups.
With respect to the interpretation of periostin levels (index test), low risk of bias was attributed if comparisons regarded samples of the same nature (serum, nasal secretions, MS or NP tissue) and unclear risk if the tests compared samples of different nature, such as NP versus MS tissues taken from different study groups. To evaluate any risk of bias regarding CRSwNP as a reference standard, we abstracted data on any analysis investigating the underlying inflammation pattern (eosinophilic, immunoglobulin [IgE] or interleukin 5 [IL-5] related), as shown in Table 1 . In case of lack of any such information, the study was considered of high risk of bias as far as CRSwNP diagnosis is concerned and classified as raising high concerns regarding the applicability of the results in CRSwNP populations.
The studies were divided into subgroups, according to the comparisons they made: 1) NP versus MS from healthy controls; CRSwNP, or CRSsNP patients; 2) MS from CRSwNP patients versus MS from controls; 3) NP from various CRSwNP endotypes or phenotypes with one another or controls,;4) serum; and 5) nasal secretions samples. Within individual studiesm, statistical significance was attributed to two-sided p < 0.05.
The prevalence of different CRSwNP endotypes may vary considerably among populations. Therefore, the lack of any investigation on the underlying inflammation patterns was classified as raising high concerns regarding reference standard applicability. To assess further risk of bias regarding reference standard and index text selections across studies, data was extracted on the methods used for the diagnosis of eosinophilic CRSwNP (E-CRSwNP) and the laboratory tests used to measure periostin levels ( Table 2 ). Data on the potential use of periostin as a biomarker were pooled.
Table 2. Summary of methods.
| N | Study | Population and Specimen | Consecutive or random | Study design | Eosinophilic diagnosis CRSwNP subgroups |
Index test |
|---|---|---|---|---|---|---|
| Comparisons between tissue samples | ||||||
| 1 | Stankovic et al., 2008 20 | CRSwNP (NP) = 10 NERD (NP) = 10 CLS (IT, ES) = 10 |
? | Prospective case-control | CRSwNP vs NERD No eosinophil reference |
IHC Microarray RNA RT-PCR |
| 2 | Platt et al., 2011 30 | CRSwNP (NP) = 10 CRSwNP (IT, MT, S, LW) = 10 CLS (IT, MT, ES, S, LW) = 10 |
? | Prospective case-control | No eosinophil reference | RT-qPCR |
| 3 | Ishida et al., 2012 9 | CRSwNP (NP) = 19 NERD (NP) = 10 CLS (IT) = 7 |
? | Prospective case-control | CRSwNP vs NERD No eosinophil reference |
IHC qRT-PCR Western blotting |
| 4 | Kim et al., 2015 10 | E (NP) = 36 NE (NP) = 45 |
? | Retrospective case-control | E if eosinophils> 10% of the inflammatory cell population | IHC qRT-PCR |
| 5 | Seshardi et al., 2015 33 | CRSwNP (UP) = 23 CLS (UP) = 18 |
? | Prospective case-control | No eosinophil reference | IHC Semi qRT-PCR |
| 6 | Shiono et al., 2015 21 | CRSwNP (NP) = 28 | ? | Retrospective | Diffuse (n = 20) vs superficial (n = 8) periostin expression in NP Shiono et al criteria for E |
IHC |
| 7 | Wang et al., 2015 22 | CRSwNP (NP) = 37 CLS (IT) = 15 CRSwNP (IT, ES) = 14 |
? | Prospective case-control | IL-5 low vs IL-5 high in NP tissue ECP, tissue and blood eosinophils in analysis |
IHC ELISA RT-PCR |
| 8 | Gevaert et al., 2017 28 | CLS (IT) = 5 CRSwNP (NP) = 15 |
? | Prospective case-control | ECP, tissue eosinophils in analysis | ELISA |
| 9 | Kim et al., 2017 23 | CLS (UP) = 22 CRSwNP (UP) = 68 CRSwNP (NP) = 67 CRSsNP (UP) = 62 NE-(NP) = 34 E-(NP) = 38 |
? | Prospective case-control | E if eosinophils> 10% of the inflammatory cell population. | Histological analysis qRT-PCR |
| 10 | Xu et al., 2017 11 | NE-(NP) = 36 E-(NP) = 30 CLS (MT) = 12 |
? | Prospective case-control | E if eosinophils> 10% of the inflammatory cell population | IHC qRT-PCR Western blotting |
| 11 | Wei et al., 2018 27 | CLS (UP) = 25 CRSwNP (NP) = 63 NE(NP) = 16 E(NP) = 18 |
Random | Prospective case-control | E if > 7 eosinophilic cells/HPF (400 × ) | IHC qRT-PCR Western blotting ELISA |
| 12 | Wu et al., 2018 12 | CLS (IT) = 10 CRSwNP (NP) = 10 |
? | Prospective case-control | E if eosinophils per HPF > 10 | Aptamer-based proteomic array and whole transcriptomic analysis |
| 13 | Wu et al., 2018 29 | CLS (IT) = 10 E-CRSwNP (NP) = 10 |
? | Prospective case-control | E if eosinophils per HPF > 10 | IHC Proteomic analysis Whole Transcriptomic Analysis |
| 15 | Nakayama et al., 2019 13 | NE-(NP) = 9 E-(NP) = 42 CLS (UP) = 13 |
Consecutive | Prospective cross-sectional | E as per JESREC | qRT-PCR Luminex 200 for protein concentration |
| 16 | Du et al., 2021 15 | CRSwNP (NP) = 37 CRSsNP (ES) = 14 CLS (IT) = 15 |
? | Prospective case-control | No eosinophil association with periostin seek | Immunoassay |
| 17 | Yilmaz et al., 2022 19 | CRSwNP (NP) = 26 CLS (IT) = 30 |
? | Prospective case-control | E if eosinophils per HPF > 10 | IHC Sandwich ELISA |
| 18 | Zhang et al., 2022 16 | Preop normosmia (NP) = 25 Preop hypoanosmia (NP) = 60 |
? | Prospective cross-sectional | T&T olfactometer for olfactory function assessment Tissue eosinophils in analysis |
IHC ELISA |
| 19 | Danielides et al., 2025 17 | CRSwNP (NP) = 36; 13/36 asthmatic CLS (?) = 12 |
Consecutive | Prospective case-control | No eosinophil reference Subgroups according to asthma and smoking |
ELISA RT-PCR Western blotting |
| 20 | Maharani et al., 2025 18 | CRSwNP(NP, UP) = 30 CLS (IT) = 8 |
Consecutive | Prospective cross-sectional | Association with ECP Dominant biomarker | ELISA |
| 21 | Suzaki et al., 2025 25 | CLS (UP) = 12 CRSwNP NE (NP) = 16 CRSwNP E (NP) = 14 |
? | Prospective case-control | E as per JESREC | IHC, ISH qRT-PCR ELISA |
| Studies on serum and/or nasal secretions | ||||||
| 22 | Asano et al., 2017 31 |
Serum
Asthma = 20 Asthma + rhinitis = 22 Asthma + CRSwNP = 13 Asthma + CRSsNP = 10 |
? | Prospective case-control | E as per JESREC | ELISA |
| 23 | Maxfield et al., 2017 32 |
Serum
CRSwNP = 33 CRSsNP = 38 CLS = 62 |
? | Prospective case-control | No eosinophil reference | ELISA |
| 24 | Xu et al., 2017 26 |
Serum
NE = 48 E = 46 |
? | Prospective case-control | E if eosinophils> 10% of the inflammatory cell population. | Sandwich ELISA |
| 25 | Wu et al., 2021 14 |
Nasal secretions
Controlled CRSwNP = 30 Uncontrolled CRSwNP = 46 |
? | Retrospective cross-sectional | Eosinophil count included in multivariate analysis | ELISA |
Abbreviations: ?, not reported; AR, allergic rhinitis; CRSwNP, chronic rhinosinusitis with nasal polyposis; CLS, controls; E, eosinophilic CRSwNP; ECP, eosinophil cationic protein; ES, ethmoid sinus; IHC, Immunohistochemistry; IHC, immunohistochemistry; ISH, in situ hybrydization analysis; IT, inferior turbinate; L-K, Lund-Kennedy score; L-M, Lund-Mackay score; LW, lateral nasal wall; MT, middle turbinate; NE, noneosinophilic CRSwNP; NERD, nonsteroidal anti-inflammatory drug exacerbated respiratory disease; NP, nasal polyp; qRT-PCR, quantitative real time PCR; RT-PCR, reverse transcription polymerase chain reaction; S, septum; SD, standard deviation; UP, uncinate process.
Results
The total number of records identified through a database search ( n = 229) was reduced to 24 after removing following the procedure presented in Fig. 1 .
Most of the studies were prospective studies on NP samples taken intraoperatively during functional endoscopic sinus surgery (for CRSwNP populations) and septoplasty (for controls), with considerable heterogeneity regarding the anatomical origin of the latter (inferior turbinate, middle turbinate, UP, ethmoid sinus). Almost all research groups have stored the tissue samples at -80°C immediately after collection until the time of protein and mRNA extraction. 9 10 11 12 13 14 15 16 17 18 One study used deparaffinized, rehydrated, and centrifuged samples to acquire a supernatant for measurements. 19 Most of the literature refers to tissue homogenates, where mechanical microdisruptions of fresh tissue permeabilized the cell membranes to extract mRNA and proteins for quantification. Only 6 of the studies conducted a localization analysis. 20 21 22 23 24 25 The majority used reverse-transcription polymerase chain reaction (RT-PCR) for mRNA expression measurements and enzyme-linked immunosorbent assay (ELISA) for protein quantification ( Table 2 ).
Heterogenous criteria have been applied for the diagnosis of E-CRSwNP; the most common one was eosinophils comprising > 10% of the inflammatory cell population. 10 11 23 26 Other researchers used the absolute count of > 7 eosinophils/high-powered field (HPF, 400 × ) 27 or > 10 eosinophils/HPF. 12 The Japan epidemiological survey of refractory eosinophilic CRS (JESREC) classification which includes peripheral blood and radiological findings is also widely accepted. 13 25 Shiono et al. 21 used the following criteria: blood eosinophilia (> 6% of total white blood cells), presence of soft tissue density in the olfactory cleft, and the posterior ethmoid sinus on computed tomography (CT).
Bronchial asthma and the use of glycocorticosteroids for at least 4 weeks before surgery was almost unanimously accepted as sources of bias ( Table 1 ). Regarding corticosteroids, most of the authors excluded patients with history of local as well as systemic use, 10 11 12 14 15 17 18 19 22 23 26 28 29 while others excluded only patients with history of systemic use. 9 13 16 20 25 30 31 Smoking 12 13 14 15 16 17 20 29 31 33 and allergic fungal rhinosinusitis 10 11 13 14 15 19 23 26 were considered as possible sources of bias by several studies. Antihistamines 10 23 and previous sinus surgery 9 16 30 were noted as potential bias in only a few studies. In the study by Wang et al., 22 tissue periostin expressions were found to be significantly upregulated in high-IL-5 compared with low-IL-5 CRSwNP patients, while they did not differ significantly between low-IL-5 CRSwNP and CRSsNP patients. 22
Patient selection concerns were raised for 9 studies ( Tables 1 3 ). Unclear risk of bias concerns regarding the index text were raised for 10 studies, solely comparing NP with control MS tissues. 9 11 12 13 14 15 17 19 20 22 27 28 The majority of studies (n = 18) provided data on E-CRSwNP diagnosis or included tissue eosinophil counts in a multivariate analysis 10 11 12 13 16 18 19 23 25 26 27 29 and were characterized as “low risk” for bias regarding CRSwNP diagnosis and “low concern” regarding the applicability of the results ( Table 3 ).
Τable 3. Summary of the results of the QUADAS-2 tool.
| Study | RoB | Applicability concerns | |||||
|---|---|---|---|---|---|---|---|
| Patient selection | Index test | Reference standard | Flow and timing | Patient selection | Index test | Reference standard | |
| Stankovic et al., 2008 20 | ☺ | ? | ☹ | ☺ | ☺ | ☺ | ☹ |
| Platt et al., 2011 30 | ☺ | ☺ | ☹ | ☺ | ☺ | ☺ | ☹ |
| Ishida et al., 2012 9 | ☺ | ☺ | ☹ | ☺ | ☺ | ☺ | ☹ |
| Kim et al., 2015 10 | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ |
| Seshardi et al., 2015 33 | ☹ | ☺ | ☹ | ☺ | ☺ | ☺ | ☹ |
| Shiono et al., 2015 21 | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ |
| Wang et al., 2015 22 | ☺ | ? | ☺ | ☺ | ☺ | ☺ | ☺ |
| Asano et al., 2017 31 | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ |
| Gevaert et al., 2017 28 | ☺ | ? | ☺ | ☺ | ☺ | ☺ | ☺ |
| Kim et al., 2017 23 | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ |
| Maxfield et al., 2017 32 | ☹ | ☺ | ☹ | ☺ | ☺ | ☺ | ☹ |
| Xu et al., 2017 26 | ☹ | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ |
| Xu et al., 2017 11 | ☹ | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ |
| Wei et al., 2018 27 | ☹ | ? | ☺ | ☺ | ☺ | ☺ | ☺ |
| Wu et al., 2018 12 | ☺ | ? | ☺ | ☺ | ☺ | ☺ | ☺ |
| Wu et al., 2018 29 | ☺ | ? | ☺ | ☺ | ☺ | ☺ | ☺ |
| Nakayama et al., 2019 13 | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ |
| Du et al., 2021 15 | ☺ | ? | ☹ | ☺ | ☺ | ☺ | ☹ |
| Wu et al., 2021 14 | ☹ | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ |
| Yilmaz et al., 2022 19 | ☹ | ? | ☺ | ☺ | ☺ | ☺ | ☺ |
| Zhang et al., 2022 16 | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ |
| Danielides et al., 2025 17 | ☹ | ? | ? | ☺ | ☺ | ☺ | ? |
| Maharani et al., 2025 18 | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ | ☺ |
| Suzaki et al., 2025 25 | ☹ | ? | ☺ | ☺ | ☺ | ☺ | ☺ |
Abbreviations: RoB, risk of bias.
Notes: Risk: ☺, low; ☹, high; and ?, unclear.
The results of the included studies are summarized in Table 4 . Few studies have focused on endotype-oriented measurements of periostin. Endotype differentiation regarded tissue eosinophilia, 10 11 13 23 27 dominant biomarker expression, 18 or high/low-IL-5 CRSwNP. 22 Only 5 studies have reported results on periostin levels in non-NP MS from patients with CRSwNP. 18 23 30 33
Table 4. Summary of results.
| Comparison | Study | Result | |||
|---|---|---|---|---|---|
| m-RNA | r-RNA | Protein | Gene expression | ||
| CRSwNP (NP) vs. CLS | Stankovic et al., 2008 20 | POSTN; CRSwNP (NP) > CLS, p < 0.01 | |||
| Platt et al., 2011 30 | 18S r-RNA; CRSwNP (NP) > CLS, FC = 7.5, p < 0.003 | ||||
| Ishida et al., 2012 9 | CRSwNP (NP) > CLS, p < 0.05 | CRSwNP (NP) > CLS, p < 0.05 | |||
| Seshardi et al., 2015 33 | CRSwNP (NP) > CLS, p < 0.001 | ||||
| Wang et al., 2015 22 |
high-IL-5 > CLS,
p
= 0.01
low-IL-5 > CLS, p = 0.41 |
||||
| Gevaert et al., 2017 28 | CRSwNP > CLS, p < 0.001 | ||||
| Kim et al., 2017 23 | CRSwNP (NP) > CLS, p < 0.0001 | CRSwNP (NP) > CLS, p < 0.05 | |||
| Wei et al., 2018 27 | CRSwNP (NP) > CLS, p < 0.001 | ||||
| Wu et al., 2018 12 | CRSwNP > CLS, FC = 3.95, p < 0.01 | ||||
| Du et al., 2021 15 | CRSwNP > CLS, p = 0.001 | ||||
| Yilmaz et al., 2022 19 | CRSwNP > CLS, p = 0.002 | ||||
| Danielides et al., 2025 17 | CRSwNP (NP) > CLS, p < 0.05 | CRSwNP (NP) > CLS, p < 0.05 | |||
| Maharani et al., 2025 18 | CRSwNP (NP) > CLS, p < 0.05 | ||||
| CRSwNP (non-NP) vs CLS | Platt et al., 2011 30 | 18S r-RNA; CRSwNP(nonNP) vs. CLS, NS | |||
| Seshardi et al., 2015 33 | CRSwNP (nonNP) vs. CLS, NS | ||||
| Kim et al., 2017 23 | CRSwNP (nonNP) > CLS, p < 0.05 | CRSwNP (nonNP) vs. CLS, NS | |||
| Maharani et al., 2025 18 | CRSwNP (nonNP) > CLS, p < 0.05 | ||||
| CRSwNP (NP) vs CRSwNP (non-NP) | Platt et al., 2011 30 | 18S r-RNA CRSwNP (NP) > CRSwNP (non-NP), p < 0.0001 | |||
| Kim et al., 2017 23 | CRSwNP (NP) > CRSwNP (non-NP), p < 0.001 | CRSwNP (NP) > CRSwNP (non-NP), p < 0.05 | |||
| Maharani et al., 2025 18 | CRSwNP (NP) > CRSwNP (non-NP), p = 0.01 | ||||
| E vs non-E CRSwNP (NP) | Kim et al., 2015 10 | ||||
| Kim et al., 2017 23 | E (NP) > nonE (NP), p < 0.01 | E (NP) > nonE (NP), p < 0.01 | |||
| Xu et al., 2017 11 | E (NP) > nonE (NP), p < 0.05 | E (NP) > nonE (NP), p < 0.05 | |||
| Wei et al., 2018 27 | E (NP) > nonE (NP), p < 0.001 | E (NP) > nonE (NP), p < 0.001 | |||
| Nakayama et al., 2019 13 | E (NP) > nonE (NP), p < 0.05 | POSTN; E (NP) vs. nonE (NP), NS |
|||
| Maharani et al., 2025 18 | No correlation with ECP | ||||
| Suzaki et al., 2025 25 | E (NP) > nonE (NP), p < 0.05 | E (NP) > nonE (NP), p < 0.01 | |||
| E-CRSwNP (NP) vs CLS | Kim et al., 2017 23 | E (NP) > CLS, p < 0.0001 | |||
| Xu et al., 2017 11 | E (NP) > CLS, p < 0.01 | E (NP) > CLS, p < 0.05 | |||
| Wu et al., 2018 29 | E (NP) > CLS, FC = 3.95, p < 0.001 | ||||
| Nakayama et al., 2019 13 | POSTN; E (NP) > CLS, p < 0.001 | ||||
| Suzaki et al., 2025 25 | E (NP) > CLS, p < 0.0001 | E (NP) > CLS, p < 0.0001 | |||
| Non-E-CRSwNP (NP) vs CLS | Xu et al., 2017 11 | NonE vs. CLS, NS | NonE vs. CLS, NS | ||
| Nakayama et al., 2019 13 | NonE vs. CLS, NS | POSTN; NonE vs. CLS, NS | |||
| Suzaki et al., 2025 25 | NonE vs. CLS, NS | NonE > CLS, p < 0.05 | |||
| CRSwNP (NP) vs NERD (NP) | Stankovic et al., 2008 20 | POSTN; CRSwNP> NERD, p = 0.01 | |||
| Ishida et al., 2012 9 | CRSwNP vs. NERD, NS | ||||
| CRSwNP (NP) vs CRSsNP | Seshardi et al., 2015 33 | CRSwNP (NP) > CRSsNP, p < 0.001 | |||
| Wang et al., 2015 22 |
high-IL-5 > CRSsNP,
p
= 0.01
low-IL-5 vs. CRSsNP, NS |
||||
| Kim et al., 2017 23 | CRSwNP (NP) > CRSsNP, p < 0.0001 | CRSwNP (NP) > CRSsNP, p < 0.01 | |||
| Du et al., 2021 15 | CRSwNP (NP) vs. CRSsNP, NS | ||||
| CRSwNP (non-NP) vs CRSsNP | Seshardi et al., 2015 33 | CRSwNP (nonNP) vs. CRSsNP, NS | |||
| Kim et al., 2017 23 | CRSwNP (nonNP) vs. CRSsNP, NS | CRSwNP (nonNP) vs. CRSsNP, NS | |||
| Serum |
Asano et al., 2017
31
(asthmatic pts) |
CRSwNP > CLS,
p
= 0.0002
CRSwNP > CRSsNP, p = 0.002 E > nonE, p = 0.02 |
|||
| Maxfield et al., 2017 32 |
CRSwNP > CLS,
p
= 0.004
CRSwNP > CRSsNP, p = 0.004 |
||||
| Xu et al., 2017 26 | Correlation with E, p = 0.022 | ||||
| Yilmaz et al., 2022 19 | CRSwNP > CLS, p < 0.001 | ||||
| Danielides et al., 2025 17 | CRSwNP vs. CLS, NS | CRSwNP vs. CLS, NS | |||
Abbreviations: CRSsNP, chronic rhinosinusitis without nasal polyposis; CRSwNP, chronic rhinosinusitis with nasal polyposis; CLS, controls; E, eosinophilic; ECP, eosinophil cationic protein; FC, fold change; mRNA, messenger ribonucleic acid; NERD, nonsteroidal anti-inflammatory drug exacerbated respiratory disease; nonE, noneosinophilic; non-NP, nonpolypoidal mucosal samples; NS, nonsignificant; POSTN, periostin gene; rRNA, ribosomal ribonucleic acid; vs, versus.
Localization analyses in Asian populations have described 3 patterns of periostin expression in NP, a “diffuse” throughout the lamina propria, a “superficial” regarding the subepithelial layers between the basement membrane and the nasal glands and a “mixed” one. The “diffuse” pattern was correlated to comorbid asthma 21 and/or E-CRSwNP. 21 24 Stankovic et al. 20 on the other hand, have observed this pattern only in their study on a Caucasian population.
Secondary outcomes verified a strong and significant correlation between mRNA transcription and protein expression levels in NP and control tissue samples, 12 29 34 despite the fact that mRNA and protein measurements refer to different parts of the mucosa ( Table 4 ). Periostin protein has been mainly localized in the subepithelial regions 22 and basement membrane, 25 while its transcripts have been mainly observed in the epithelium of NP tissue. 22 25 Following these findings, Wang et al. 22 concluded that epithelial cells are probably the main cells producing periostin, which is then deposited into the subepithelial region of a mature NP.
A strong and significant correlation has been also shown between different ELISA methods of measuring serum periostin. 35 However, some kits have been consistently attributing higher levels than others, as a result of two factors. First, the lack of standardization of the periostin laboratory samples processing and assay workflow for either electrochemiluminescence or ELISA methods. 36 Second, the fact that periostin can appear in multiple isoforms at proportions that, according to studies on asthmatic populations, may differ between tissues and disease states. 36 Also, ELISA platforms present differences in monoclonal antibodies' affinities for periostin isoforms and, consequently, different isoform mixtures may attribute substantially different numerical results. 31
On the other hand, serum periostin expression does not necessarily correlate with local mucosal expression. In the study of Wang et al. 22 patients with high mucosal IL-5 expression demonstrated significantly higher mucosal periostin levels than patients with low IL-5 expression, whereas they did not differ in their serum periostin concentrations.
Quantitative synthesis of the studies' results is impeded for two reasons. First, the aforementioned discrepancies between different laboratory kits prohibit numerical comparisons of periostin levels resulting from different platforms. 36 Second, the included studies refer to populations with substantial or unknown heterogeneity regarding high-risk bias factors, such as disease severity, comorbidities, and endotypes, 8 with the eosinophilic/noneosinophilic endotyping additionally being subject to different definition criteria. Qualitative synthesis, however, attributed the results presented in Table 4 .
Regarding endotypes, periostin upregulation in terms of both protein and mRNA only refer to NP tissue samples from patients with E-CRSwNP. 10 11 13 23 25 27 29 This protein's levels and mRNA levels in NP tissue samples from patients with nonE-CRSwNP were significantly lower than E-CRSwNP samples, 10 11 13 23 25 27 and similar to controls. 11 13
The limited literature seems to agree that periostin upregulation refers to mature NP rather than the adjacent non-polypoidal mucosa.
The differences between mature NP tissue samples and nonpolypoidal MS collected from adjacent anatomical sites within the same CRSwNP patients were only assessed by 3 studies. 18 23 30 Both periostin protein 23 25 and mRNA levels 23 have been reported as significantly higher in NP than adjacent ÙP samples. In the study by Platt et al., 30 18S r-RNA periostin levels are significantly higher in NP than adjacent MS from the septum, inferior turbinate, middle turbinate, and lateral nasal wall (overlying the lacrimal sac). On the other hand, Maharani et al. 18 reported that periostin protein levels significantly correlated with eosinophils cationic protein levels in UP samples of patients with CRSwNP, but not in their NP samples.
In the few studies comparing MS and controls, controversial results have been reported. Two studies have concluded that UP samples collected from CRSwNP patients are similar to normal controls in terms of periostin m-RNA, 33 while one study reported significantly higher periostin m-RNA levels in UP. 23 The MS from septum, inferior turbinate, middle turbinate, and the area overlying the lacrimal sac did not differ from controls in one study of periostin r-RNA 30 levels. Finally, regarding periostin protein levels, nonpolypoidal UP samples from CRSwNP patients were found to be similar to controls in one study 23 and significantly higher than controls in another. 25
It is also noteworthy that MS collected from CRSwNP patients were found to be comparable to samples from CRSsNP in terms of both m-RNA 23 33 and protein 23 periostin levels.
The differences in the synthesis and characteristics of the study populations, as well as in the origin of the samples, the methods used to measure periostin levels, and the criteria applied to diagnose E-CRSwNP, may all implement cross-studies bias ( Tables 1 2 3 4 ). Publication bias may also apply, since studies reporting nonsignificant results often remain unpublished.
Multivariate regression analysis (adjusted for asthma, sex, smoking, NERD, oral/nasal steroids' use, and number of previous sinus surgeries) demonstrated that the presence of NP was an independent predictor of higher serum periostin levels. 32 On the other hand, the clinical validity of periostin as a biomarker for the differential diagnosis between non-E/E-CRSwNP has been questioned, 26 unless used as part of combinatorial biomarker algorithms. 10 26 Similarly, although periostin levels in NP samples 27 and serum 24 have been associated with polyp recurrence after endoscopic surgery, its actual clinical validity as a recurrence biomarker is rather low, both in serum 24 and nasal secretion samples. 14
Discussion
Results are summarized in Table 4 .
The literature is currently lacking data on periostin levels in the nonpolypoidal sites of the CRSwNP mucosa, thus raising questions on whether it actually contributes to the pathogenesis or is eventually found as a by-product of polyp formation. According to the available studies, periostin upregulation in tissue samples applies to mature eosinophilic NP. Comparisons between NP and nonpolypoidal MS of patients with CRSwNP attributed significantly higher protein, mRNA and 18SrRNA periostin levels in the former. 18 23 30
Comparisons between nonpolypoidal mucosa samples of CRSwNP patients and controls have attributed controversial results, being in some studies comparable in terms of periostin protein, 23 mRNA, 33 and rRNA expression 30 or, in other studies, significantly higher than controls in terms of periostin m-RNA 23 and protein 18 levels. No significant regional variation in periostin gene, 18SrRNA, or protein expression was measured between nonpolypoidal mucosa of the septum, inferior turbinate, middle turbinate, ethmoid labyrinth, or lateral nasal wall in either CRSwNP patients or control subjects. 20 30
Endotype-oriented measurements of periostin levels are currently lacking. Eosinophilic NP (eNP) samples exhibited significantly higher mRNA and protein levels than non-eosinophilic in most studies, 10 11 13 23 25 27 with similar tissue goblet cell hyperplasia and collagen deposition. 27 A significant correlation between the number of eosinophils and the mRNA or protein expression levels of periostin in NP has been advocated by most studies, 19 37 although controversial results have also been reported. 18
The main sources of periostin deposited in eNP are mast cells 23 and nasal epithelial cells. 22 23 25 27 Its contribution to persistent and progressive eosinophilic inflammation and NP formation has been advocated with regard to three aspects. 11 22 38 First, the positive association between periostin protein immunoreactivity and basement membrane thickness, as well as goblet cell hyperplasia. 27 In vitro studies suggested that periostin may stimulate NP-derived fibroblasts to produce vascular endothelial growth factor (VEGF), thus increasing microvascular permeability and local angiogenesis, 11 21 39 as well as eotaxin-2 and Regulated on Activation Normal T-Cell Expressed and Secreted (RANTES), thus further triggering inflammation. 11
Second, the speculation that periostin may contribute to eosinophil localization in NP, can be based on its adherence to IL-5-stimulated eosinophils in vitro. 22 40 Periostin is, however, unlikely to contribute significantly to the recruitment of eosinophils into NPs, since it has not been correlated with eotaxin or tissue eosinophil cationic protein expression or tissue or blood eosinophil numbers. 22 25
A third possible pathway of contribution to E-CRSwNP can be identified through the positive association between periostin and IL-5. Periostin has been significantly correlated with IL-4, 5, and 13 expression in NP samples, 22 23 25 27 33 41 while paired comparisons between NP and nonpolypoidal UP samples of the same patients revealed highly significant differences only for IL-5 and periostin. 42 Therefore, one could assume that although up-regulation of periostin during type-2 inflammation is substantially dependent on IL-4 and 13 signaling, 22 23 25 27 33 43 the progression toward a mature polyp out of the inflamed mucosa seems to require additional pathogenetic factors that may, among others, result in the persistence of high periostin and IL-5 levels. 23 25 27 In a limited number of studies on NP, nasal secretions, or serum, high periostin levels have been associated with other molecules as well, such as 15-LOX-1, 37 thymic stromal lymphopoietin (TSLP), 27 matrix metalloproteinase-3 (MMP-3), 15 tissue inhibitor of metalloproteinases-2 (TIMP-2), 15 cystatin, 14 and IgG4, 44 but the relevant underlying mechanisms remain obscure
Little is known about the mechanisms regulating the systematic or local periostin production in CRSwNP patients and controls. This may explain the heterogeneity of the patient selection bias investigated by the included studies ( Tables 1 3 ). Only 2 studies 9 15 state to have interpreted periostin measurements without knowledge of the clinical diagnosis and origin of the specimens, but this is probably of little importance when referring to rather objective methods, such as ELISA and qRT-PCR (quantitative real time PCR).
Final Comments
The present study has approached the subject with special consideration to the origin of the specimens and the CRSwNP endotype, highlighting two important results. First, periostin upregulation in NP is highly associated with the eosinophilic and high-IL-5 CRSwNP inflammatory patterns, while non-e-NP are comparable to controls. Second, upregulation of periostin refers to NP samples, while periostin levels in nonpolypoidal mucosa samples of CRSwNP patients are comparable to controls and CRSsNP patients. Further similarly oriented research is needed to understand the role of periostin upregulation in the pathogenesis or preservation of eNP.
Funding Statement
Funding The authors declare that they did not receive funding from agencies in the public, private or non-profit sectors to conduct the present study.
Conflict of Interest The authors have no conflict of interests to declare.
Data Availability
Data will be available upon request to the corresponding author.
Editor-in-Chief: Geraldo Pereira Jotz.
References
- 1.Norris R A, Damon B, Mironov V, et al. Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues. J Cell Biochem. 2007;101(03):695–711. doi: 10.1002/jcb.21224. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Ebenezer J A, Christensen J M, Oliver B G, et al. Periostin as a marker of mucosal remodelling in chronic rhinosinusitis. Rhinology. 2017;55(03):234–241. doi: 10.4193/Rhino16.215. [DOI] [PubMed] [Google Scholar]
- 3.Izuhara K, Nunomura S, Nanri Y, et al. Periostin in inflammation and allergy. Cell Mol Life Sci. 2017;74(23):4293–4303. doi: 10.1007/s00018-017-2648-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Moher D, Shamseer L, Clarke M. et al. PRISMA-P Group . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(01):1. doi: 10.1186/2046-4053-4-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Whiting P F, Rutjes A W, Westwood M E. et al. QUADAS-2 Group . QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(08):529–536. doi: 10.7326/0003-4819-155-8-201110180-00009. [DOI] [PubMed] [Google Scholar]
- 6.Won H K, Kim Y C, Kang M G, et al. Age-related prevalence of chronic rhinosinusitis and nasal polyps and their relationships with asthma onset. Ann Allergy Asthma Immunol. 2018;120(04):389–394. doi: 10.1016/j.anai.2018.02.005. [DOI] [PubMed] [Google Scholar]
- 7.Daniel W W. New York: John Wiley & Sons; 1999. Determination of Sample Size for Estimating Means; pp. 198–190. [Google Scholar]
- 8.Alanzi O A, AlBlaies W F, Elnadif I A, Riga M G. Biases related to periostin levels in chronic rhinosinusitis with nasal polyposis: a systematic review. Rhinology. 2024;62(01):13–22. doi: 10.4193/Rhin23.220. [DOI] [PubMed] [Google Scholar]
- 9.Ishida A, Ohta N, Suzuki Y, et al. Expression of pendrin and periostin in allergic rhinitis and chronic rhinosinusitis. Allergol Int. 2012;61(04):589–595. doi: 10.2332/allergolint.11-OA-0370. [DOI] [PubMed] [Google Scholar]
- 10.Kim D K, Jin H R, Eun K M, et al. Non-Eosinophilic Nasal Polyps Shows Increased Epithelial Proliferation and Localized Disease Pattern in the Early Stage. PLoS One. 2015;10(10):e0139945. doi: 10.1371/journal.pone.0139945. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Xu M, Chen D, Zhou H, Zhang W, Xu J, Chen L. The Role of Periostin in the Occurrence and Progression of Eosinophilic Chronic Sinusitis with Nasal Polyps. Sci Rep. 2017;7(01):9479. doi: 10.1038/s41598-017-08375-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Wu D, Mueller S K, Nocera A L, Finn K, Libermann T A, Bleier B S. Axonal Guidance Signaling Pathway Is Suppressed in Human Nasal Polyps. Am J Rhinol Allergy. 2018;32(04):208–216. doi: 10.1177/1945892418773558. [DOI] [PubMed] [Google Scholar]
- 13.Nakayama T, Sugimoto N, Okada N, et al. JESREC score and mucosal eosinophilia can predict endotypes of chronic rhinosinusitis with nasal polyps. Auris Nasus Larynx. 2019;46(03):374–383. doi: 10.1016/j.anl.2018.09.004. [DOI] [PubMed] [Google Scholar]
- 14.Wu D, Yan B, Wang Y, Wang C H, Zhang L. Prognostic and pharmacologic value of cystatin SN for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2021;148(02):450–460. doi: 10.1016/j.jaci.2021.01.036. [DOI] [PubMed] [Google Scholar]
- 15.Du K, Wang M, Zhang N, et al. Involvement of the extracellular matrix proteins periostin and tenascin C in nasal polyp remodeling by regulating the expression of MMPs. Clin Transl Allergy. 2021;11(07):e12059. doi: 10.1002/clt2.12059. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Zhang Z, Liu J, Xie L, Cao W, Ma F, Zhang Y. Tissue eosinophils and mucous inflammatory cytokines for the evaluation of olfactory recovery after endoscopic sinus surgery in patients with nasal polyposis. Am J Otolaryngol. 2022;43(05):103561. doi: 10.1016/j.amjoto.2022.103561. [DOI] [PubMed] [Google Scholar]
- 17.Danielides G, Lygeros S, Kyriakopoulos G, et al. Serum and Tissue Periostin Expression in Rhinosinusitis With Nasal Polyps. Am J Rhinol Allergy. 2025;39(04):259–265. doi: 10.1177/19458924251332546. [DOI] [PubMed] [Google Scholar]
- 18.Maharani I, Fitri L E, Djajalaksana S, Handoko E, Pradana Y A. The correlation between periostin and eosinophillic cationic protein demonstrate its potential biomarker of mucosal remodeling in chronic rhinosinusitis with nasal polyps . Acta Otolaryngol. 2025;145(06):515–521. doi: 10.1080/00016489.2025.2486615. [DOI] [PubMed] [Google Scholar]
- 19.Yilmaz G O, Cetinkaya E A, Eyigor H, et al. The diagnostic importance of periostin as a biomarker in chronic rhinosinusitis with nasal polyp. Eur Arch Otorhinolaryngol. 2022;279(12):5707–5714. doi: 10.1007/s00405-022-07492-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Stankovic K M, Goldsztein H, Reh D D, Platt M P, Metson R. Gene expression profiling of nasal polyps associated with chronic sinusitis and aspirin-sensitive asthma. Laryngoscope. 2008;118(05):881–889. doi: 10.1097/MLG.0b013e31816b4b6f. [DOI] [PubMed] [Google Scholar]
- 21.Shiono O, Sakuma Y, Komatsu M, et al. Differential expression of periostin in the nasal polyp may represent distinct histological features of chronic rhinosinusitis. Auris Nasus Larynx. 2015;42(02):123–127. doi: 10.1016/j.anl.2014.09.003. [DOI] [PubMed] [Google Scholar]
- 22.Wang M, Wang X D, Zhang N, et al. Association of periostin expression with eosinophilic inflammation in nasal polyps. J Allergy Clin Immunol. 2015;136(06):1700–1.703E12. doi: 10.1016/j.jaci.2015.09.005. [DOI] [PubMed] [Google Scholar]
- 23.Kim D W, Kulka M, Jo A, et al. Cross-talk between human mast cells and epithelial cells by IgE-mediated periostin production in eosinophilic nasal polyps. J Allergy Clin Immunol. 2017;139(05):1692–1.695E9. doi: 10.1016/j.jaci.2016.09.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Ninomiya T, Noguchi E, Haruna T, et al. Periostin as a novel biomarker for postoperative recurrence of chronic rhinosinitis with nasal polyps. Sci Rep. 2018;8(01):11450. doi: 10.1038/s41598-018-29612-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Suzaki I, Hirabayashi E, Teguchi Y, et al. IL-13-Induced Periostin Expression is Increased in Eosinophilic Chronic Rhinosinusitis Int Forum Allergy Rhinol 20251508767–778. 10.1002/alr.23559PubMed [DOI] [PubMed] [Google Scholar]
- 26.Xu M, Zhang W, Chen D, Zhou H, Chen L. Diagnostic significance of serum periostin in eosinophilic chronic sinusitis with nasal polyps. Acta Otolaryngol. 2018;138(04):387–391. doi: 10.1080/00016489.2017.1388540. [DOI] [PubMed] [Google Scholar]
- 27.Wei Y, Ma R, Zhang J, et al. Excessive periostin expression and Th2 response in patients with nasal polyps: association with asthma. J Thorac Dis. 2018;10(12):6585–6597. doi: 10.21037/jtd.2018.11.12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Gevaert E, Zhang N, Krysko O, et al. Extracellular eosinophilic traps in association with Staphylococcus aureus at the site of epithelial barrier defects in patients with severe airway inflammation. J Allergy Clin Immunol. 2017;139(06):1849–1.86E9. doi: 10.1016/j.jaci.2017.01.019. [DOI] [PubMed] [Google Scholar]
- 29.Wu D, Mueller S K, Nocera A L, Finn K, Libermann T A, Bleier B S. TREM-1 Neutrophil Activation Pathway Is Suppressed in Eosinophilic Nasal Polyps. Am J Rhinol Allergy. 2018;32(05):359–368. doi: 10.1177/1945892418782233. [DOI] [PubMed] [Google Scholar]
- 30.Platt M P, Soler Z M, Kao S Y, Metson R, Stankovic K M. Topographic gene expression in the sinonasal cavity of patients with chronic sinusitis with polyps. Otolaryngol Head Neck Surg. 2011;145(01):171–175. doi: 10.1177/0194599811402030. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Asano T, Kanemitsu Y, Takemura M, et al. Serum Periostin as a Biomarker for Comorbid Chronic Rhinosinusitis in Patients with Asthma. Ann Am Thorac Soc. 2017;14(05):667–675. doi: 10.1513/AnnalsATS.201609-720OC. [DOI] [PubMed] [Google Scholar]
- 32.Maxfield A Z, Landegger L D, Brook C D, et al. Periostin as a Biomarker for Nasal Polyps in Chronic Rhinosinusitis. Otolaryngol Head Neck Surg. 2018;158(01):181–186. doi: 10.1177/0194599817737967. [DOI] [PubMed] [Google Scholar]
- 33.Seshadri S, Lu X, Purkey M R, et al. Increased expression of the epithelial anion transporter pendrin/SLC26A4 in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2015;136(06):1548–1.558E10. doi: 10.1016/j.jaci.2015.05.024. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Workman A D, Nocera A L, Mueller S K, Otu H H, Libermann T A, Bleier B S. Translating transcription: proteomics in chronic rhinosinusitis with nasal polyps reveals significant discordance with messenger RNA expression. Int Forum Allergy Rhinol. 2019;9(07):776–786. doi: 10.1002/alr.22315. [DOI] [PubMed] [Google Scholar]
- 35.Matsumoto H. Roles of Periostin in Asthma. Adv Exp Med Biol. 2019;1132:145–159. doi: 10.1007/978-981-13-6657-4_15. [DOI] [PubMed] [Google Scholar]
- 36.Arron J R, Izuhara K. Asthma biomarkers: what constitutes a ‘gold standard’? Thorax. 2015;70(02):105–107. doi: 10.1136/thoraxjnl-2014-206069. [DOI] [PubMed] [Google Scholar]
- 37.Imoto Y, Takabayashi T, Sakashita M, et al. Enhanced 15-Lipoxygenase 1 Production is Related to Periostin Expression and Eosinophil Recruitment in Eosinophilic Chronic Rhinosinusitis. Biomolecules. 2020;10(11):1568. doi: 10.3390/biom10111568. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Conway S J, Izuhara K, Kudo Y, et al. The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci. 2014;71(07):1279–1288. doi: 10.1007/s00018-013-1494-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Han D Y, Cho J S, Moon Y M, et al. Effect of prostaglandin e2 on vascular endothelial growth factor production in nasal polyp fibroblasts. Allergy Asthma Immunol Res. 2013;5(04):224–231. doi: 10.4168/aair.2013.5.4.224. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Johansson M W, Annis D S, Mosher D F. α(M)β(2) integrin-mediated adhesion and motility of IL-5-stimulated eosinophils on periostin. Am J Respir Cell Mol Biol. 2013;48(04):503–510. doi: 10.1165/rcmb.2012-0150OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Dennis S K, Lam K, Luong A. A Review of Classification Schemes for Chronic Rhinosinusitis with Nasal Polyposis Endotypes. Laryngoscope Investig Otolaryngol. 2016;1(05):130–134. doi: 10.1002/lio2.32. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Kim D K, Eun K M, Kim M K, et al. Comparison Between Signature Cytokines of Nasal Tissues in Subtypes of Chronic Rhinosinusitis. Allergy Asthma Immunol Res. 2019;11(02):201–211. doi: 10.4168/aair.2019.11.2.201. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Hamilton J D, Harel S, Swanson B N, et al. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy. 2021;51(07):915–931. doi: 10.1111/cea.13954. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Oka A, Ninomiya T, Fujiwara T, et al. Serum IgG4 as a biomarker reflecting pathophysiology and post-operative recurrence in chronic rhinosinusitis. Allergol Int. 2020;69(03):417–423. doi: 10.1016/j.alit.2019.12.004. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Data will be available upon request to the corresponding author.
